Clinical trials: Semaglutide
Menopause, Menopause Hot Flashes
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
What if midlife women, who are inherently at an increased risk for future cardiometabolic disease due to transitioning into menopause, had access to a suite of evidence-based health interventions? Could these interventions reduce…
- Conditions
- Menopause, Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular
- Trial name
- NCT06975111
- Testing
- Metformin, semaglutide, Anti-hypertensives
- Where
- 3 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Non-alcoholic Steatohepatitis
A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations
Novo Nordisk is developing a combination of 2 medicines (NNC0194-0499 and semaglutide) for the treatment of nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT05766709
- Testing
- NNC0194-0499, Semaglutide, NNC0194-0499/Semaglutide A (40/3.20 mg/mL)
- Where
- Canada
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Caloric Restriction, Body Composition
Long-Term Effects of Semaglutide on Body Composition and Performance in Running
Semaglutide, a GLP-1 receptor agonist, has demonstrated significant weight-loss effects in people with obesity and/or type 2 diabetes, but its impact on exercise performance among lean, fit athletes remains unknown.
- Conditions
- Caloric Restriction, Body Composition, Performance
- Trial name
- NCT07874932
- Testing
- Semaglutide (SEMA)
- Where
- Denmark
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Morten Hostrup, PhD
Tobacco Use
Impact of Semaglutide on Tobacco Use and Related Health Behaviors
This pilot randomized trial will assess the impact of 12 weeks of semaglutide administration (vs placebo) on changes in: (i) tobacco use and related factors (nicotine craving, withdrawal, motivation to quit, etc.) and (ii)…
- Trial name
- ONSET (NCT06986993)
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Oklahoma
Obesity
WEgovy Real World Assessment of Weight Loss in Korea
This study is to investigate the effectiveness and safety of Wegovy (semaglutide) in Korean patients living with obesity in routine clinical practice.
- Trial name
- NCT07280221
- Testing
- Semaglutide
- Where
- 18 sites in South Korea
- Volunteers
- 500 people
- Sponsor
- Novo Nordisk A/S
Obesity & Overweight, Type 2 Diabetes
A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults
- Trial name
- NCT07539415
- Testing
- DWRX5003, DWC202502, DWC202503
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes, Coronary Artery Disease
Semaglutide Treatment On Coronary Progression
The purpose of this research study is to see the effect of the diabetes medicine Semaglutide on a condition called atherosclerosis.
- Trial name
- STOP (NCT03985384)
- Testing
- Semaglutide 2 MG/1.5 ML Subcutaneous Solution
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Pediatric Obesity, Metabolic and Bariatric Surgery
Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth
This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery).
- Conditions
- Pediatric Obesity, Metabolic and Bariatric Surgery, Semaglutide
- Trial name
- NCT06934655
- Testing
- Semaglutide 2.4 mg
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's Hospital Los Angeles
Healthy Volunteers, Type 2 Diabetes
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (C) Semaglutide Tablets
In this study two different tablets for oral use of a known investigational medicinal product, called semaglutide, will be tested.
- Trial name
- NCT04109508
- Testing
- Oral semaglutide
- Where
- Germany
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Monogenic Obesity
A Multicenter Pharmacoepidemiological Cohort on Real Life Use of Semaglutide in Adolescents or Adults With Monogenic Obesity
Rare genetic forms of obesity, so called monogenic obesity are linked to alteration in energy balance involving hypothalamic pathways.
- Trial name
- ObGeSema (NCT06380426)
- Where
- 2 sites in France
- Volunteers
- 175 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Obesity
A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss
This observational study is designed to determine the feasibility of recruitment from a digital research community of people using an anti-obesity medication for weight loss to understand willingness to consent to survey research…
- Trial name
- COSMOS-DIGITAL (NCT06761703)
- Testing
- TAP® Micro Select Device (Touch Activated Phlebotomy)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy Volunteers (Diabetes Mellitus, Type 2)
A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide
In this trial, two approved solutions of the medicine semaglutide will be compared in healthy volunteers. The purpose of this trial is to see if semaglutide B and semaglutide D solutions are comparable with regards to moving…
- Trial name
- NCT05232708
- Testing
- Semaglutide B, 1.34 mg/mL, Semaglutide D, 1.0 mg/mL
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels.
- Trial name
- PIONEER REAL (NCT05443568)
- Testing
- Oral semaglutide
- Where
- Israel
- Volunteers
- 155 people
- Sponsor
- Novo Nordisk A/S
Psoriasis (PsO), Obesity and Overweight
Effect of Semaglutide in Patients With Psoriasis and Obesity
Obesity is well known to be an important comorbidity of psoriasis. It gives rise to higher risk of psoriatic arthritis, more severe disease and also poorer response to biologics.
- Trial name
- SEMPSO (NCT06937060)
- Testing
- semaglutide
- Where
- Hong Kong
- Volunteers
- 14 people
- Sponsor
- The University of Hong Kong
Diabetes Mellitus, Type 2, Nicotine Dependence, Cigarettes
Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients
Diabetes has become an increasingly serious global health issue. In 2024, approximately 537 million adults were living with diabetes, and this number is projected to rise to 783 million by 2045, representing a 46% increase.
- Trial name
- NCT06924697
- Testing
- Application of GLP-1RAs drugs, DPP-4i group
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai East Hospital
Diabetes Mellitus, Insulin Sensitivity
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
The primary objective of Study GZQG is to compare the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment.
- Trial name
- NCT06982859
- Testing
- Retatrutide, Semaglutide
- Where
- Germany
- Volunteers
- 95 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema.
- Trial name
- REIMAGINE 1 (NCT06323174)
- Testing
- Cagrilintide, Semaglutide
- Where
- 50 sites in United States, China and 5 more
- Volunteers
- 189 people
- Sponsor
- Novo Nordisk A/S
Gastric Retention
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention
A prospective, single-center, observational study to compare the risk of gastric retention between the exposure group (with neuropathy) and non-exposure group (without neuropathy) in diabetic patients receiving uninterrupted…
- Trial name
- NCT07156591
- Testing
- Esophagogastroduodenoscopy
- Where
- China
- Volunteers
- 460 people
- Sponsor
- Fudan University
Diabetes, Healthy
Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects
This trial is conducted in Europe. The aim of the trial is to investigate the absorption, metabolism and excretion after a single subcutaneous dose of [3H]-semaglutide in healthy male subjects.
- Trial name
- NCT02060266
- Testing
- semaglutide
- Where
- Netherlands
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Obesity
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
- Trial name
- NCT02453711
- Testing
- semaglutide, liraglutide
- Where
- 74 sites in United States, Australia and 6 more
- Volunteers
- 957 people
- Sponsor
- Novo Nordisk A/S